MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/dom.70150

Медицинская библиотека · Diabetes, obesity & metabolism · 2025

Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.

Di Molfetta Sergio, Di Gioia Ludovico, Caruso Irene, Caporusso Mariangela, Trerotoli Paolo, Natalicchio Annalisa, Perrini Sebastio, Laviola Luigi, Giorgino Francesco

Систематический обзорСтатьяМетаанализПеревод в очереди

Аннотация

AIMS: To provide an updated analysis of the performance of different hybrid closed loop (HCL) systems in randomised controlled trials (RCTs) on subjects with type 1 diabetes.

MATERIALS AND

METHODS

We conducted a systematic review with meta-analysis. We searched four online databases and performed hand-searching of conference proceedings to find studies from inception to 18 April 2025. We included RCTs enrolling subjects with type 1 diabetes, evaluating commercial HCL systems against other insulin therapy regimens, with a duration of intervention ≥2 weeks, and reporting time in range (TIR) as an outcome. Studies involving pregnant women were excluded.

RESULTS

A total of 37 studies evaluating seven different HCL systems (CamAPS Fx, Control IQ, DBLG1, iLet BP, MiniMed 670G, MiniMed 780G, and Omnipod 5) were included. In studies with a mean age < 18 years, mean TIR was 64.1% (95% CI: 61-67.2), ranging from 59.3% (95% CI: 49.6-69.1) with MiniMed 780G to 68% (95% CI: 65.8-70.3) with Control IQ, and end-of-study HbA1c was 7.4% (95% CI: 7-7.7), ranging from 6.7% (95% CI: 6.6-6.9) with CamAPS Fx to 7.9% (95% CI: 6.9-9) with MiniMed 780G. In studies with a mean age ≥ 18 years, mean TIR was 70.8% (95% CI: 68.6-73), ranging from 63.1% (95% CI: 59.4-66.8) with Omnipod 5 to 74.4% (95% CI: 69.7-79.1) with MiniMed 780G, and end-of-study HbA1c was 7.1% (95% CI: 7-7.3), ranging from 7.0% (95% CI: 6.9-7.1) with Control IQ to 7.2% (95% CI: 7-7.5) with MiniMed 670G.

CONCLUSIONS

In RCTs, commercial HCL systems show different achievements of CGM metrics and HbA1c in people with type 1 diabetes.

Для цитирования: Di Molfetta Sergio, Di Gioia Ludovico, Caruso Irene, Caporusso Mariangela, Trerotoli Paolo, Natalicchio Annalisa, Perrini Sebastio, Laviola Luigi, Giorgino Francesco. Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.. Diabetes, obesity & metabolism. 2025. DOI: 10.1111/dom.70150.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.